Stock Financial Ratios


AKTX / Akari Therapeutics Plc financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price4.51
Volume102,000.00
Market Cap ($M)5,476.27
Enterprise Value ($M)5,096.87
Book Value ($M)48.72
Book Value / Share0.04
Price / Book118.13
NCAV ($M)48.77
NCAV / Share0.06
Price / NCAV86.36
Income Statement (mra) ($M)
Revenue0.00
EBITDA-30.58
Net Income-45.32
Balance Sheet (mrq) ($M)
Cash & Equivalents61.43
Cash / Share0.05
Assets62.96
Liabilities16.60
Quick Ratio3.30
Current Ratio3.30
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.93
Return on Assets (ROA)-0.65
Return on Equity (ROE)-0.93
Identifiers and Descriptors
CUSIP00972G108
Central Index Key (CIK)1541157
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
009726108
Share Statistics
Common Shares Outstanding (M)1,177.69
Scoring Models
Piotroski F Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Inventory Work In Progress Per Share0.00
Property Plant And Equipment Net Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Debt Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Additional Paid In Capital Per Share0.10
Assets Per Share0.07
Cash And Equivalents Per Share0.07
Assets Other Non Current Per Share0.00
Liabilities Other Non Current Per Share0.00
Intangibles Per Share0.00
Goodwill Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Liabilities Per Share0.02
Assets Current Per Share0.07
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Inventory Finished Goods Per Share0.00
Equity Per Share0.05
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share0.00
Retained Earnings Per Share-0.07
Liabilities Current Per Share0.02
Liabilities And Stock Equity Per Share0.07
Cash Per Share0.05

Related News Stories

Top Biopharma Events Coming by the End of 2017

2017-10-28 247wallst
As the markets continue to hit all-time highs, biotech and pharmaceutical companies have been part of these massive gains. There is a very positive sentiment in the health care sector as it’s been one of the best performing this year, second to technology, in the S&P 500. (374-16)

Corporate News Blog - Akari Therapeutics Announces Enrolment of Additional Patients in COBALT Phase-II Clinical Trial of Coversin(TM)

2017-10-13 accesswire
LONDON, UK / ACCESSWIRE / October 13, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Akari Therapeutics, PLC (NASDAQ: AKTX) ("Akari"), following which, we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=AKTX. The Company announced on October 11, 2017, the enrolment of three additional patients in the ongoing Phase-II COBALT clinical trial of Coversin™ in patients with paroxysmal nocturnal hemoglobinuria (PNH). (32-0)

BRIEF-Akari Therapeutics announces further clinical progress

2017-10-11 reuters
* Akari Therapeutics - 3 additional patients have been enrolled in ongoing Phase II Cobalt clinical trial of Coversin in patients with PNH​ (17-1)

An In-Depth Look At Alexion's Competition And Upcoming Catalysts

2017-10-10 seekingalpha
Alexion Pharmaceuticals, Inc. (ALXN) is a biopharmaceutical company with three marketed drugs, a promising pipeline member in ALXN1210, and a market cap of over $31 billion. ALXN’s major source of revenue, however, a drug called eculizumab (marketed as Soliris), may face competition in the future. Evaluating the viability of the threat posed by ALXN’s competitors is a key step before opening or closing a position and the focus of this article. (168-0)

Akari Therapeutics: What's Next For This 'Busted IPO'?

2017-10-04 seekingalpha
Today we look at Akari Therapeutics, a biotech 'Busted IPO' that has had a wild ride so far in 2017. (57-2)

CUSIP: 00972G108